Runjia

Runjia Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics. The company's research efforts are primarily focused on three core therapeutic areas: oncology, infectious diseases, and bone and joint disorders. Its lead clinical asset, RP902, is a potent cap-dependent endonuclease inhibitor currently in late-stage development for the treatment of influenza. Additionally, Runjia is advancing RP606, a novel TrkA inhibitor designed to provide non-opioid pain relief for patients with osteoarthritis. With integrated R&D centers and manufacturing facilities in Shanghai and Suzhou, the company is positioned to manage the full lifecycle of drug development. Runjia has successfully secured significant venture capital funding to support its mission of providing high-quality, affordable innovative medicines.